(Q38207924)

English

Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins

scientific article published on June 2014

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Mycobacterium tuberculosis

0 references

drug interaction

0 references

Alberto Matteelli

object named as

Alberto Matteelli

4

0 references

author name string

Mario Regazzi

1

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Anna Cristina Carvalho

2

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Paola Villani

3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

publication date

1 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

489-507

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Timing of initiation of antiretroviral drugs during tuberculosis therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Integration of antiretroviral therapy with tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Initiating antiretrovirals during tuberculosis treatment: a drug safety review

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Multidrug- and extensively drug-resistant TB in persons living with HIV.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Update on rifampin and rifabutin drug interactions

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic interactions with rifampicin : clinical relevance

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

The clinical pharmacokinetics of rifabutin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Rifapentine for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Clinical Pharmacokinetics of Rifampicin

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic interactions between etravirine and non-antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetic interaction between fosamprenavir-ritonavir and rifabutin in healthy subjects

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART

1 reference

https://api.crossref.org/works/10.1007%2FS40262-014-0144-3

21 January 2018

Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifabutin for treating pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience of raltegravir-containing regimens in HIV-infected patients during rifampicin-containing treatment of tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of a Clinically Meaningful Pharmacokinetic Effect of Rifabutin on Raltegravir: In Vitro/In Vivo Correlation

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifapentine--a long-acting rifamycin for tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of double-dose raltegravir in two patients with HIV infection and tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24777631

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40262-014-0144-3

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38207924&oldid=2201407406"